Norset (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonising postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic neurotransmission. Its additional H1 histamine receptor antagonism contributes to sedation and appetite stimulation.

The appropriate dose of Norset is determined individually by a qualified prescriber based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional medical guidance.

The safety of Norset (mirtazapine) in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and discuss alternative options with the patient before prescribing.

To order Norset, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), Norset (mirtazapine) has a distinct mechanism that often results in stronger sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss. However, SSRIs may have a lower risk of weight gain and sedation.

Norset tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Norset is taken orally as a tablet. It should be swallowed whole with a glass of water, preferably in the evening due to its sedative properties, unless the prescriber advises a different schedule.

Serious risks include agranulocytosis or neutropenia, seizures, severe hypotension, hepatic dysfunction, and the emergence or worsening of suicidal thoughts, especially during the initial weeks of treatment. Patients should seek immediate medical attention if they experience any of these symptoms.

Norset should not be used by individuals with known hypersensitivity to mirtazapine or any of its excipients, and it is contraindicated in patients who have taken monoamine oxidase inhibitors (MAOIs) within the past 14 days. Caution is also advised for patients with severe hepatic impairment.